| scholarly article | Q13442814 |
| P50 | author | Patrizia Agostinis | Q30111808 |
| Abhishek D. Garg | Q38322540 | ||
| Louis Boon | Q89457618 | ||
| Stefaan Van Gool | Q96142102 | ||
| Carolien A M Koks | Q114531668 | ||
| Lien Vandenberk | Q114575324 | ||
| Tina Verschuere | Q114575350 | ||
| P2860 | cites work | The Cancer Genome Atlas Pan-Cancer analysis project | Q24606808 |
| A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death | Q24620548 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis | Q27348437 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| Calreticulin exposure dictates the immunogenicity of cancer cell death | Q28280438 | ||
| The somatic genomic landscape of glioblastoma | Q28300185 | ||
| Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients | Q28730798 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Java Treeview--extensible visualization of microarray data | Q29547226 | ||
| Open source clustering software | Q29547702 | ||
| Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy | Q29619961 | ||
| Immunogenic Cell Death in Cancer Therapy | Q29620118 | ||
| The immune contexture in human tumours: impact on clinical outcome | Q29620667 | ||
| Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice | Q30493889 | ||
| Immunocompetent murine models for the study of glioblastoma immunotherapy | Q33574853 | ||
| Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model | Q33613430 | ||
| Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma | Q33613584 | ||
| Prognostic value of the preoperative immunological profile in patients with glioblastoma | Q33887213 | ||
| Tumour-infiltrating T-cell subpopulations in glioblastomas | Q33943553 | ||
| Dendritic-cell-based therapeutic cancer vaccines | Q34360094 | ||
| Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy | Q34399765 | ||
| Clinical use of dendritic cells for cancer therapy. | Q34421850 | ||
| Predicting the "usefulness" of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey | Q34515718 | ||
| CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. | Q34721530 | ||
| Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines | Q35027034 | ||
| Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide | Q35167257 | ||
| PROGgeneV2: enhancements on the existing database | Q35527541 | ||
| Dendritic Cell-Based Vaccines that Utilize Myeloid Rather than Plasmacytoid Cells Offer a Superior Survival Advantage in Malignant Glioma. | Q35763478 | ||
| Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma | Q35765180 | ||
| Regulatory T cells are not a strong predictor of survival for patients with glioblastoma | Q35789008 | ||
| Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma | Q35815273 | ||
| Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies | Q35828467 | ||
| Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma | Q35863183 | ||
| Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components | Q36092658 | ||
| Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death | Q36301061 | ||
| PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress | Q36311137 | ||
| Impact of temozolomide on immune response during malignant glioma chemotherapy | Q36362798 | ||
| Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal | Q36413628 | ||
| Epigenetic biomarkers of T-cells in human glioma. | Q36484129 | ||
| Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma | Q36609839 | ||
| Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. | Q36639475 | ||
| The prognostic landscape of genes and infiltrating immune cells across human cancers | Q36857285 | ||
| Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study | Q37011021 | ||
| Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. | Q37154132 | ||
| Danger signalling during cancer cell death: origins, plasticity and regulation. | Q37381745 | ||
| DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. | Q37395354 | ||
| Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas | Q37435455 | ||
| The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma | Q37471704 | ||
| Dendritic cell therapy of high-grade gliomas. | Q37594834 | ||
| MyD88: A Critical Adaptor Protein in Innate Immunity Signal Transduction | Q38069571 | ||
| From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer | Q38098366 | ||
| Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity | Q38174601 | ||
| Targeting adaptive glioblastoma: an overview of proliferation and invasion | Q38235930 | ||
| Active dendritic cell immunotherapy for glioblastoma: Current status and challenges | Q38301084 | ||
| BNIP3 supports melanoma cell migration and vasculogenic mimicry by orchestrating the actin cytoskeleton | Q38593285 | ||
| ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death | Q39135022 | ||
| Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy | Q40321304 | ||
| Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin | Q41436818 | ||
| Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models. | Q41710325 | ||
| Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death | Q41744540 | ||
| Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. | Q42218510 | ||
| Photodynamic therapy of nonmelanoma skin cancer with topical hypericum perforatum extract--a pilot study | Q42523363 | ||
| A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis | Q42871258 | ||
| Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. | Q45945651 | ||
| Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level | Q46459126 | ||
| Prognostic significance and mechanism of Treg infiltration in human brain tumors. | Q48170914 | ||
| CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas | Q48313295 | ||
| Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme | Q48467671 | ||
| Hypericin for visualization of high grade gliomas: first clinical experience | Q48689562 | ||
| Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. | Q48973528 | ||
| Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. | Q54618275 | ||
| Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. | Q55463248 | ||
| NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. | Q55463555 | ||
| Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. | Q55467906 | ||
| Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis | Q56993328 | ||
| Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine | Q58032919 | ||
| P433 | issue | 328 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell death | Q2383867 |
| dendritic cell | Q506253 | ||
| P304 | page(s) | 328ra27 | |
| P577 | publication date | 2016-03-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma | |
| P478 | volume | 8 |
| Q44876957 | A melanin-mediated cancer immunotherapy patch |
| Q38921652 | Advances and challenges: dendritic cell vaccination strategies for glioblastoma. |
| Q47569046 | Advances in immunotherapeutic research for glioma therapy. |
| Q28078649 | Autophagy-Dependent Secretion: Contribution to Tumor Progression |
| Q28067203 | Boosting Tumor-Specific Immunity Using PDT |
| Q45160319 | Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. |
| Q47614555 | Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. |
| Q50433335 | Collagen I enhances the efficiency and anti-tumor activity of dendritic-tumor fusion cells |
| Q38708463 | Computed determination of the in vitro optimal chemocombinations of sphaeropsidin A with chemotherapeutic agents to combat melanomas |
| Q90629204 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death |
| Q92263929 | Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis |
| Q38928826 | DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing. |
| Q49679692 | Defining the role of the tumor vasculature in antitumor immunity and immunotherapy |
| Q90362022 | Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity |
| Q36201736 | Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis |
| Q89347786 | Dendritic cell-based immunotherapy |
| Q92995626 | Dendritic cells in cancer immunology and immunotherapy |
| Q38851464 | Developing immunotherapeutic strategies to target brain tumors |
| Q57817490 | Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy |
| Q49370635 | Drug-induced ciliogenesis in pancreatic cancer cells is facilitated by the secreted ATP-purinergic receptor signaling pathway |
| Q47233214 | E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox |
| Q39585070 | Editorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality |
| Q39441238 | Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance. |
| Q39381281 | Engineering challenges for brain tumor immunotherapy |
| Q55190117 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. |
| Q59135320 | Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma |
| Q50566797 | Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy |
| Q33594333 | Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity |
| Q92626019 | Honokiol-enhanced cytotoxic T lymphocyte activity against cholangiocarcinoma cells mediated by dendritic cells pulsed with damage-associated molecular patterns |
| Q97531602 | Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment |
| Q49805006 | Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development. |
| Q64107945 | Immunogenic Cell Death and Immunotherapy of Multiple Myeloma |
| Q92835955 | Immunogenic cell death in cancer therapy: Present and emerging inducers |
| Q42378527 | Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy |
| Q98223086 | Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors |
| Q90656057 | Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study |
| Q42639856 | Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival |
| Q48170351 | Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4+ T cells combined with agonist α-GITR mAb promotes durable CD8+ T-cell-dependent antitumor immunity |
| Q90697648 | Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine |
| Q90053615 | Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination |
| Q48344360 | Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide |
| Q47843948 | Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. |
| Q98159129 | Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy |
| Q40319033 | Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing |
| Q90021097 | Photodynamic Therapy and Immunity: An Update |
| Q89975467 | Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma |
| Q64890734 | Photodynamic therapy mediated immune therapy of brain tumors. |
| Q98726595 | Photodynamic therapy regulates fate of cancer stem cells through reactive oxygen species |
| Q88885196 | Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus |
| Q33809573 | Phytochemicals Approach for Developing Cancer Immunotherapeutics |
| Q38438763 | Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. |
| Q60914597 | Recent Advances in Oncolytic Virotherapy and Immunotherapy for Glioblastoma: A Glimmer of Hope in the Search for an Effective Therapy? |
| Q33683101 | Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy |
| Q64057061 | Strategies for developing and optimizing cancer vaccines |
| Q47745185 | Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity |
| Q47135720 | Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma |
| Q92598503 | Synthetic lethality between VPS4A and VPS4B triggers an inflammatory response in colorectal cancer |
| Q90646039 | The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire |
| Q91828247 | The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological Treatment Of Ovarian Cancer Cells |
| Q39178065 | The Microenvironmental Landscape of Brain Tumors |
| Q38930244 | The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors |
| Q47863483 | The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy |
| Q53109846 | Trial watch: Dendritic cell-based anticancer immunotherapy |
| Q56594845 | Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics |
| Q89457645 | Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology |
| Q90080201 | Type I interferons and endoplasmic reticulum stress in health and disease |
| Q40081800 | Uncovering the immunotherapeutic cycle initiated by p19Arf and interferon-β gene transfer to cancer cells: An inducer of immunogenic cell death |
Search more.